MEIP News and Press, MEI Pharma Inc. From 11/09/23

2023-11-09 17:42:54 ET More on MEI Pharma Seeking Alpha’s Quant Rating on MEI Pharma Historical earnings data for MEI Pharma For further details see: MEI Pharma GAAP EPS of $8.46, revenue of $65.3M

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the quarter ended September 30, 2023 and highlighted recent corporate events. ...

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced it will participate in the Stifel 2023 Healthcare Conference. David Urso, president and chief executive officer, will present a company overview and business upd...

2023-11-06 17:02:43 ET More on MEI Pharma MEI Pharma, Inc. (MEIP) Q4 2023 Earnings Call Transcript MEI Pharma GAAP EPS of -$4.78 beats by $0.92, revenue of $48.82M beats by $0.53M MEI Pharma FY 2023 Earnings Preview Seeking Alpha’s Quant Rating on MEI ...

MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that pursuant to the previously disclosed cooperation agreement with Anson Funds and Cable Car Capital, the Company’s Board ...

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that an abstract highlighting clinical data from the monotherapy dose escalation stage of the ongoing Phase 1 study evaluating voruciclib, a selective oral cycli...

Commits to Capital Return of Up to $3.15 per Share Adds Three New Directors and Forms Capital Allocation Committee of the Board MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) and Anson Funds and Cable Car Capital (“Anson and Cable Car”) today announc...

Files Definitive Consent Revocation Statement Mails Letter to Stockholders Highlighting the Path to Realizing the Full Value of Their MEI Investment Urges Stockholders Not to be Misled by Anson Advisors and Cable Car Capital and Not to Consent to Their Agenda MEI Pharma,...

- Responds to Substantial Stock Accumulation by Anson Advisors and Cable Car Capital - - Protects Long-Term Value of All Stockholders’ Investments in MEI Pharma - MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies f...

2023-09-29 13:51:22 ET More on Infinity Pharmaceuticals Infinity Pharmaceuticals receives delisting determination letter from Nasdaq Infinity Pharma cuts jobs, seeking "strategic transaction" for eganelisib Financial information for Infinity Pharmaceuticals F...